- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00235469
A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy and Safety OF 200, 400, AND 600 mg/Day SPM 927 in Subjects With Painful Distal Diabetic Neuropathy
This phase 2b trial is being conducted at approximately 60 sites in the US to investigate whether lacosamide (SPM 927) at different doses reduces pain in subjects with diabetic neuropathy. Approximately 360 subjects will be randomized to placebo or one of three doses of lacosamide. To qualify for this trial, subjects with symptoms of painful distal diabetic neuropathy ranging in duration from 6 months to 5 years must have an average pain intensity of ≥4 on an 11-point Likert scale (0-10 scale) during the 7 day period prior to start of treatment.
To determine what effect lacosamide has on diabetic neuropathic pain, subjects will use a diary to record their daily pain intensity (morning and evening), pain interference with sleep (morning) and activity (evening). Use of rescue medication (acetaminophen) and subjects' quality of life will be investigated. In addition, safety and tolerability of the different doses of lacosamide will be investigated.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
North Carolina
-
RTP, North Carolina, United States
- Schwarz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Painful distal diabetic neuropathy
Exclusion Criteria:
- Must have an average pain intensity of ≥ 4 on an 11-point Likert scale
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To investigate the efficacy of 200, 400, and 600 mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.
|
Secondary Outcome Measures
Outcome Measure |
---|
To investigate the effect of lacosamide on subjects' perception of pain, sleep, activity, quality of life, as well as to investigate the pharmacokinetics and safety of lacosamide.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP0742
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Neuropathy
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
Imperial College LondonActegy Ltd.Not yet recruitingDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic ComplicationUnited Kingdom
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
AbbVie (prior sponsor, Abbott)CompletedDiabetic Neuropathies | Diabetic Neuropathy, Painful | Diabetic Polyneuropathy | Diabetic Neuralgia | Neuralgia, DiabeticUnited States, Canada, France, Germany, Italy, Mexico, Puerto Rico
-
Tanta UniversityActive, not recruiting
-
October 6 UniversityCompletedDiabetic Neuropathy PeripheralEgypt
-
Power Life Sciences Inc.Not yet recruitingDiabetic Neuropathies | Diabetic Neuropathy Peripheral
-
Khyber Medical University PeshawarActive, not recruitingPeripheral Diabetic NeuropathyPakistan
Clinical Trials on SPM 927
-
UCB PharmaCompletedDiabetic NeuropathiesUnited States
-
UCB PharmaCompletedEpilepsies, PartialUnited States
-
UCB PharmaCompletedPartial Seizures With or Without Secondary GeneralizationGermany
-
UCB PharmaCompleted
-
UCB PharmaCompleted
-
UCB PharmaCompleted
-
UCB PharmaSCHWARZ BIOSCIENCES GmbH - Part of UCB GroupCompletedPainful Diabetic NeuropathyGermany
-
UCB PharmaCompletedChronic Refractory Neuropathic PainGermany
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan